USE OF MONOCLONAL-ANTIBODY MBR1 TO DETECT MICROMETASTASES IN BONE-MARROW SPECIMENS OF BREAST-CANCER PATIENTS
USE OF MONOCLONAL-ANTIBODY MBR1 TO DETECT MICROMETASTASES IN BONE-MARROW SPECIMENS OF BREAST-CANCER PATIENTS
复制标题
DOI：
10.1016/0277-5379(90)90185-v
复制
发表时间：
1990-01-01
影响因子：
8.4
通讯作者：
COLNAGHI, MI
中科院分区：
文献类型：
--
作者：
SALVADORI, B;SQUICCIARINI, P;COLNAGHI, MI
121例乳腺癌患者术后立即采集骨髓标本，采用单克隆抗体MBr1免疫荧光法检测其他诊断方法无法检测到的肿瘤细胞。淋巴结阴性80例，阳性41例。在121例病例中，20例（16.5%）MBr1阳性。在淋巴结阴性和淋巴结阳性病例中，MBr1阳性没有差异（17%对15%）。关于临床结果（中位随访48个月），27名女性复发，包括20名mbr1阳性患者中的6名和101名mbr1阴性患者中的24名。以首次远处转移或疾病进展死亡为终点。多变量分析显示，在考虑其他预后因素后，MBr1阳性的额外贡献可以忽略不计。
Bone marrow specimens obtained from 121 breast cancer patients immediately after surgery were examined by an immunoflourescence method with monoclonal antibody MBr1 to detect tumour cells undetectable by other diagnostic procedures. 80 women were node-negative and 41 node-positive. In no case could conventional histology demonstrate tumour cells, whereas MBr1 was positive in 20 (16.5%) of the 121 cases. No difference was observed in MBr1 positivity between node-negative and node-positive cases (17% vs. 15%). With regard to clinical outcome (median follow-up 48 months) 27 women relapsed, including 6 of 20 MBr1-positive and 24 of 101 MBr1-negative patients. First distant metastases or death from progression of disease were taken as end-points. Multivariate analysis showed that the additional contribution of MBr1 positivity, after making allowance for other prognostic factors, was negligible.